Spots Global Cancer Trial Database for KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Official Title: A Phase Ib Study to Evaluate Efficacy, Safety and Tolerability of KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Study ID: NCT04040699

Conditions

HER2 Positive Solid Tumor

Interventions

KN026 combined with KN046

Study Description

Brief Summary: This is a phase Ib, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN026 combined with KN046 in subjects with advanced HER2 positive solid tumors.

Detailed Description: The study is composed of 2 stages. Stage 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 consists of 4 tumor type expansion cohorts for expanding the information on clinical safety, clinical pharmacokinetics and antitumor activity in HER2 positive patients.